CoChat

Cefiderocol resistance genomics in sequential chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients

López-Causapé, Carla, Maruri-Aransolo, Ainhize, Gomis-Font, María A., Penev, Iván, Castillo, María García, Mulet, Xavier, de Dios Caballero, Juan, Campo, Rosa del, Cantón, Rafael, Oliver, Antonio · 2023 · Clinical Microbiology and Infection
Cited by 34

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cmi.2022.11.014

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 31

  1. Oliver, 2000, High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection, Science, 288, 1251, 10.1126/science.288.5469.1251 · DOI · Paper page
  2. López-Causapé, 2018, The versatile mutational resistome of Pseudomonas aeruginosa, Front Microbiol, 9, 685, 10.3389/fmicb.2018.00685 · DOI · Paper page
  3. Tabak, 2019, Incremental clinical and economic burden of suspected respiratory infections due to multi-drug-resistant Pseudomonas aeruginosa in the United States, J Hosp Infect, 103, 134, 10.1016/j.jhin.2019.06.005 · DOI
  4. Tacconelli, 2018, Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis, Lancet Infect Dis, 18, 318, 10.1016/S1473-3099(17)30753-3 · DOI · Paper page
  5. Horcajada, 2019, Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections, Clin Microbiol Rev, 32, 10.1128/CMR.00031-19 · DOI · Paper page
  6. Del Barrio-Tofiño, 2020, Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update, Int J Antimicrob Agents, 56, 10.1016/j.ijantimicag.2020.106196 · DOI · Paper page
  7. Oliver, 2015, The increasing threat of Pseudomonas aeruginosa high-risk clones, Drug Resist Updat, 21–22, 41, 10.1016/j.drup.2015.08.002 · DOI · Paper page
  8. Parkins, 2018, Epidemiology, biology, and impact of clonal Pseudomonas aeruginosa infections in cystic fibrosis, Clin Microbiol Rev, 31, 10.1128/CMR.00019-18 · DOI · Paper page
  9. Ciofu, 2015, Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients, Adv Drug Deliv Rev, 85, 7, 10.1016/j.addr.2014.11.017 · DOI · Paper page
  10. Schick, 2018, Rapid diversification of Pseudomonas aeruginosa in cystic fibrosis lung-like conditions, Proc Natl Acad Sci U S A, 115, 10714, 10.1073/pnas.1721270115 · DOI
  11. Mena, 2008, Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation, J Bacteriol, 190, 7910, 10.1128/JB.01147-08 · DOI · Paper page
  12. Rossi, 2021, Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis, Nat Rev Microbiol, 19, 331, 10.1038/s41579-020-00477-5 · DOI · Paper page
  13. Canton, 2022, Treatment of carbapenem-resistant Pseudomonas aeruginosa infections: a case for cefiderocol, Expert Rev Anti Infect Ther, 20, 1077, 10.1080/14787210.2022.2071701 · DOI
  14. Sato, 2019, Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin, Clin Infect Dis, 69, S538, 10.1093/cid/ciz826 · DOI · Paper page
  15. Marvig, 2015, Convergent evolution and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis, Nat Genet, 47, 57, 10.1038/ng.3148 · DOI · Paper page
  16. López-Causapé, 2017, Evolution of the Pseudomonas aeruginosa mutational resistome in an international Cystic Fibrosis clone, Sci Rep, 7, 5555, 10.1038/s41598-017-05621-5 · DOI · Paper page
  17. Cortes-Lara, 2021, Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis, Clin Microbiol Infect, 27, 1631, 10.1016/j.cmi.2021.05.011 · DOI
  18. López-Causapé, 2013, Clonal dissemination, emergence of mutator lineages and antibiotic resistance evolution in Pseudomonas aeruginosa cystic fibrosis chronic lung infection, PLoS One, 8, 10.1371/journal.pone.0071001 · DOI
  19. García-Castillo, 2012, Emergence of a mutL mutation causing multilocus sequence typing-pulsed-field gel electrophoresis discrepancy among Pseudomonas aeruginosa isolates from a cystic fibrosis patient, J Clin Microbiol, 50, 1777, 10.1128/JCM.05478-11 · DOI
  20. Vettoretti, 2009, Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients, Antimicrob Agents Chemother, 53, 1987, 10.1128/AAC.01024-08 · DOI
  21. Fraile-Ribot, 2018, Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa, J Antimicrob Chemother, 73, 658, 10.1093/jac/dkx424 · DOI · Paper page
  22. Simner, 2021, Cefiderocol activity against clinical Pseudomonas aeruginosa isolates exhibiting ceftolozane-tazobactam resistance, Open Forum Infect Dis, 8, 10.1093/ofid/ofab311 · DOI
  23. Wunderink, 2021, Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial, Lancet Infect Dis, 21, 213, 10.1016/S1473-3099(20)30731-3 · DOI · Paper page
  24. Bassetti, 2021, Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial, Lancet Infect Dis, 21, 226, 10.1016/S1473-3099(20)30796-9 · DOI · Paper page
  25. Nordmann, 2022, Mechanisms of reduced susceptibility to cefiderocol among isolates from the CREDIBLE-CR and APEKS-NP clinical trials, Microb Drug Resist, 28, 398, 10.1089/mdr.2021.0180 · DOI
  26. Tümmler, 2005, Pyoverdine receptor: a case of positive Darwinian selection in Pseudomonas aeruginosa, J Bacteriol, 187, 3289, 10.1128/JB.187.10.3289-3292.2005 · DOI
  27. Luscher, 2018, TonB-dependent receptor repertoire of Pseudomonas aeruginosa for uptake of siderophore-drug conjugates, Antimicrob Agents Chemother, 62, 10.1128/AAC.00097-18 · DOI · Paper page
  28. Ito, 2017, In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria, Antimicrob Agents Chemother, 62
  29. Klein, 2022, Rapid development of cefiderocol resistance in carbapenem-resistant Enterobacter cloacae during therapy is associated with heterogeneous mutations in the catecholate siderophore receptor cirA, Clin Infect Dis, 74, 905, 10.1093/cid/ciab511 · DOI
  30. Werth, 2022, Evolution of cefiderocol resistance in Stenotrophomonas maltophilia using in vitro serial passage techniques, JAC Antimicrob Resist, 4, dlac011, 10.1093/jacamr/dlac011 · doi:10.1093/jacamr/dlac011
  31. McElheny, 2021, In vitro evolution of cefiderocol resistance in an NDM-producing Klebsiella pneumoniae due to functional loss of cirA, Microbiol Spectr, 9, 10.1128/Spectrum.01779-21 · DOI

Cited by

See all 34

Metadata

Authors
López-Causapé, C., Maruri-Aransolo, A., Gomis-Font, M. A., Penev, I., Castillo, M. G., Mulet, X., de Dios Caballero, J., Campo, R. D., Cantón, R., & Oliver, A.
Venue
Clinical Microbiology and Infection
Publisher
Elsevier BV
Published
2023-04
Volume
29
Issue
4
Pages
538.e7-538.e13
ISSN
1198-743X
Cited by
34
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cefiderocol resistance genomics in sequential chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients. https://app.cochat.ai/papers/10.1016/j.cmi.2022.11.014
The paper
López-Causapé, C., Maruri-Aransolo, A., Gomis-Font, M. A., Penev, I., Castillo, M. G., Mulet, X., de Dios Caballero, J., Campo, R. D., Cantón, R., & Oliver, A. (2023). Cefiderocol resistance genomics in sequential chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2022.11.014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.